Orion sues Wockhardt over US Stalevo patents
This article was originally published in Scrip
Executive Summary
OrionCorporation has filed suit in a US court against WockhardtUSA and Wockhardt Limited, alleging patent infringement related to their generic version of the Parkinson’s disease treatment Stalevo (carbidopa plus entacapone and levodopa), thus triggering a 30-month stay of approval while the legal challenge is fought.